Key result
ANGPTL3 inactivating antibody reduces TG, LDL-C, and HDL-C in dyslipidemic mice and monkeys.
This review outlines the mechanisms by which ANGPTL3 deficiency lowers all major lipoprotein classes, supporting the development of ANGPTL3 inhibitors for the treatment of combined hyperlipidemia and ASCVD risk reduction.
No takes yet. Share an insight, caveat, or question.
Does not yet support clinical use; extends preclinical rationale for ANGPTL3 inhibition in combined hyperlipidemia.
Tikka et al. (2016) studied familial combined hypobetalipoproteinemia (FHBL2). ANGPTL3 inactivating antibody was evaluated on Reduction in plasma levels of TG, LDL-cholesterol, and HDL-cholesterol. ANGPTL3 inactivating antibody administration reduced circulating plasma levels of TG, LDL-cholesterol, and HDL-cholesterol in dyslipidemic mice and monkeys.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: